Newron Pharmaceuticals has announced the successful completion of patient enrollment in its STARS (Sarizotan for the Treatment of Apneas in Rett Syndrome) clinical study.
04 Feb 2019
18 Jan 2019
Vaccinex has completed subject enrollment for the SIGNAL trial, which is a phase 2, multi-center, randomized, double-blind, placebo controlled study in subjects with early manifest and late prodromal Huntington’s disease (HD) to assess the safety, tolerability, pharmacokinetics, and efficacy of VX15/2503 (pepinemab).
26 Nov 2018
Actinogen Medical has enrolled the final patient into XanADu, a phase 2 clinical trial to evaluate Xanamem in the treatment of patients with mild Alzheimer’s disease.
09 Nov 2018
UK-based 4D pharma has commenced patient enrollment for a phase 2 clinical trial to evaluate its single-strain live biotherapeutic candidate Blautix to treat Irritable Bowel Syndrome (IBS).
02 Nov 2018
Verona Pharma has completed patient enrollment for a phase 2 trial for its nebulized RPL554 as an add-on to dual therapy using long-acting anti-muscarinic / long-acting beta2-agonists (LAMA/LABA) and triple therapy (LAMA/LABA with an inhaled corticosteroid) in the maintenance treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD).
26 Oct 2018
Bristol-Myers Squibb (BMS) has dosed the first subject in a clinical trial assessing the safety, pharmacokinetics and pharmacodynamics of BMS-986179, an investigational anti-CD-73 antibody, using Halozyme Therapeutics' Enhanze drug delivery technology.
15 Oct 2018
Mereo BioPharma Group, a UK-based specialty biopharma company, has completed patient enrollment for a phase 2b clinical trial of BPS-804 (Setrusumab) for the treatment of osteogenesis imperfecta (OI).
21 Feb 2018
Orano Med and RadioMedix have recruited first three patients in the AlphaMedix phase 1 clinical trial.
13 Feb 2018
Diurnal Group has completed patient enrolment in its European pivotal Phase III clinical trial of Chronocort (modified release hydrocortisone) for the treatment of congenital adrenal hyperplasia (CAH) in adults.